Presumed gabapentin-induced myoclonus in two cats

被引:0
作者
Buckley, Caroline [1 ]
Griffin, Croix [1 ]
Anderson, Heather [1 ]
Moore, Sarah A. [1 ,2 ]
机构
[1] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, 601 Vernon L Tharp St, Columbus, OH 43210 USA
[2] BluePearl Sci, Tampa, FL USA
来源
JOURNAL OF FELINE MEDICINE AND SURGERY OPEN REPORTS | 2024年 / 10卷 / 02期
关键词
Gabapentin; myoclonus; gabapentin-induced myoclonus; gabapentin adverse effects; PHARMACOKINETICS; SEROTONIN; DISEASE;
D O I
10.1177/20551169241273634
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Case series summary This case report describes the history and presentation of two cats with presumed gabapentin-induced myoclonus. Although this phenomenon is well documented in people, there are no previous reports in cats. Both cats in the current report had International Renal Interest Society (IRIS) stage 2 chronic kidney disease, a history of seizures (one generalized, one focal), and received gabapentin before veterinary hospital visits to alleviate anxiety (doses in the range of 11.8-16.4 mg/kg). While in the hospital, both cats were noted to have intermittent short jerks of the head that were different from the seizure activity previously noted by their owners at home. These cases appear to be the first published reports of this potential adverse effect of gabapentin in cats and risk factors in the present cases mirror those described in people.Relevance and novel information Clinicians should be aware of the potential for this phenomenon in cats receiving recommended doses of gabapentin, and future studies should focus on the role of chronic kidney disease and other neurologic conditions as risk factors for development of this condition.
引用
收藏
页数:4
相关论文
共 50 条
  • [32] Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain
    Bannister, Kirsty
    Qu, Chaoling
    Navratilova, Edita
    Oyarzo, Janice
    Xie, Jennifer Yanhua
    King, Tamara
    Dickenson, Anthony H.
    Porreca, Frank
    PAIN, 2017, 158 (12) : 2386 - 2395
  • [33] Gabapentin–induced severe myoclonus in a patient with impaired renal function
    M. Holtkamp
    A. Halle
    H. Meierkord
    F. Masuhr
    Journal of Neurology, 2006, 253 : 382 - 383
  • [34] Gabapentin for opioid-related myoclonus in cancer patients
    Mercadante, S
    Villari, P
    Fulfaro, F
    SUPPORTIVE CARE IN CANCER, 2001, 9 (03) : 205 - 206
  • [35] A pilot study of transdermal gabapentin in cats
    Slovak, Jennifer E.
    Costa, Ana P.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2021, 35 (04) : 1981 - 1987
  • [36] Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review
    Kim, Jung Bin
    Jung, Jin-Man
    Park, Moon-Ho
    Lee, Eun Ju
    Kwon, Do-Young
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 382 : 36 - 39
  • [37] REVERSIBLE INTERMITTENT RHYTHMIC MYOCLONUS WITH FLUOXETINE IN PRESUMED PICKS-DISEASE
    LAUTERBACH, EC
    MOVEMENT DISORDERS, 1994, 9 (03) : 343 - 346
  • [38] Vitamin E protects against gabapentin-induced chronic hepatic and renal damage associated with the inhibition of apoptosis and tissue injury in rats
    Welson, Nermeen N.
    Rofaeil, Remon R.
    Ahmed, Sabreen Mahmoud
    Gaber, Shereen S.
    Batiha, Gaber El-Saber
    Shahataa, Mary Girgis
    LIFE SCIENCES, 2021, 267
  • [39] Pregabalin produces similar effects as gabapentin for preanesthetic sedation in cats
    Madan, Rahul D.
    Cenani, Alessia
    Montgomery, Elizabeth
    Azevedo, Tatiana
    Vernau, Karen M.
    Brosnan, Robert J.
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2024, 262 (03): : 359 - 363
  • [40] Gabapentin-Induced Adrenal Insufficiency: The Hypothalamic-Pituitary-Adrenal Axis Stress Misresponse and Risk of Infection: A Case Report and Literature Review
    Pechlivanidou, Evmorfia
    Chatzikyriakos, Alexandros
    Zisi, Maria Anna
    Paraskevopoulos, Nikolaos
    Kaltsa, Semeli
    Konstantas, Orestis K.
    Zogakis, Panteleimon
    Catsouli, Aikaterini
    Sekouris, Nick
    Margariti, Rodanthi E.
    PHARMACEUTICALS, 2024, 17 (09)